Ribavirin
Mostrando 1-12 de 271 artigos, teses e dissertações.
-
1. Treatment of Hepatitis C with Direct-Acting Antivirals does not Induce Significant Arrhythmias
Abstract Background Chronic Hepatitis C (CHC) therapy with direct-acting antivirals (DAAs) has high efficacy and safety, but some cases of bradyarrhythmias have been described. Objective To evaluate heart rhythm disorders during DAA treatments. Methods Forty-eight patients with CHC (mean 61 years of age; 56% males; 73% HCV genotype 1) were evaluated be
International Journal of Cardiovascular Sciences. Publicado em: 2022
-
2. ASSESSING PREDICTORS OF DIRECTLY ACTING ANTIVIRALS’ FAILURE AS A FURTHER STEP TOWARDS MORE EFFICIENT HCV ELIMINATION PROGRAMS: IL28B (IFNL4) GENE POLYMORPHISM HAS NO ROLE WHILE HIGHER ESTIMATED CREATININE CLEARANCE IS A FORGOTTEN FACTOR
RESUMO Contexto: As taxas de resposta virológica sustentada (SVR) após ação direta de antivirais (DAAs) para o vírus da hepatite C (VHC) excedem 95%. Isso encorajou os formuladores de políticas a colocar planos para alcançar a eliminação do VHC até 2030. O percentual remanescente de não-respondedores pode afetar as estratégias de erradicação d
Arquivos de Gastroenterologia. Publicado em: 2022
-
3. Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
Objective: Depression has been associated with hepatitis C, as well as with its treatment with proinflammatory cytokines (i.e., interferon). The new direct-acting antiviral agents (DAAs) have minimal adverse effects and high potency, with a direct inhibitory effect on non-structural viral proteins. We studied the incidence and associated factors of depressi
Braz. J. Psychiatry. Publicado em: 2020-02
-
4. Recurrent hepatitis C treatment with direct acting antivirals – a real life study at a Brazilian liver transplant center
Recurrent hepatitis C (HCV) after liver transplantation (LT) is an important cause of morbidity and mortality. Antiviral treatment is recommended to avoid unfavorable outcomes. Direct-acting antivirals (DAA) have transformed HCV treatment, with higher efficacy and fewer side-effects than interferon-based therapies traditionally used. To evaluate DAA treatmen
Braz J Med Biol Res. Publicado em: 05/08/2019
-
5. Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
Objective: Depression has been associated with hepatitis C, as well as with its treatment with proinflammatory cytokines (i.e., interferon). The new direct-acting antiviral agents (DAAs) have minimal adverse effects and high potency, with a direct inhibitory effect on non-structural viral proteins. We studied the incidence and associated factors of depressi
Braz. J. Psychiatry. Publicado em: 15/07/2019
-
6. Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review
ABSTRACT Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment after liver transplantation. However, pegylated interferon may still be required for genotype 3 n
Rev. Inst. Med. trop. S. Paulo. Publicado em: 14/02/2019
-
7. An eye on hepatitis C: a review
RESUMO Esta revisão objetiva alertar os oftalmologistas sobre as consequências oculares que levam ao diagnóstico da infecção pelo vírus da Hepatite C. Além disso, neste contexto, os efeitos de drogas antigas e novas são discutidos no cenário oftalmológico. A importância do diagnóstico precoce e do tratamento curativo da doença tem sido relatada
Arq. Bras. Oftalmol.. Publicado em: 24/01/2019
-
8. First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients
Abstract INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HCV). The aim of this study was to analyze the effectiveness
Rev. Soc. Bras. Med. Trop.. Publicado em: 2018-04
-
9. Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil
Abstract INTRODUCTION: In 2013, combination therapy using peginterferon, ribavirin, and boceprevir or telaprevir was introduced to treat hepatitis C virus genotype 1 infection in Brazil. The effectiveness of this therapy in four Brazilian regions was evaluated. METHODS: Clinical and virological data were obtained from patients of public health institutio
Rev. Soc. Bras. Med. Trop.. Publicado em: 2018-02
-
10. Quality of life in Brazilian patients with treated or untreated chronic hepatitis C
ABSTRACT Introduction: Multiple factors negatively affect the quality of life of patients infected with hepatitis C virus. This study aims to evaluate the effect of pharmacological treatment on the quality of life of these individuals. Methods: This is a cross-sectional study conducted in two Southern Brazilian centers that used two instruments (a generic
Rev. Inst. Med. trop. S. Paulo. Publicado em: 21/12/2017
-
11. Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus
ABSTRACT Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC
Rev. Inst. Med. trop. S. Paulo. Publicado em: 06/11/2017
-
12. Profile of HIV subtypes in HIV/HBV- and HIV/HCV-coinfected patients in Southern Brazil
Abstract INTRODUCTION: HIV and viral hepatitis infections are major causes of chronic disease worldwide and have some similarities with regard to routes of transmission, epidemiology, front barriers faced during access of treatment, and strategies for a global public health response. The objective was to describe the HIV-1 subtypes, viral tropism and single
Rev. Soc. Bras. Med. Trop.. Publicado em: 2017-08